Study record
Urolithin A and muscle endurance in older adults, 65-90 (Liu et al., 2022)
Human RCT — functional endpoint
○ Evidence tier 3 — Human RCT — functional endpoint
Record verify: primary source pending
| Design | Randomized, double-blind, placebo-controlled trial (functional/biomarker) |
| DOI | 10.1001/jamanetworkopen.2021.44279 |
| Citation status | doi verified via Crossref 2026-07-12 (JAMA Netw Open 2022;5(1):e2144279, Liu et al., 'Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults'). PMID + NCT: needs_primary_fulltext. |
Five-qualifier claim
| Species / population | Older adults aged 65-90 (randomized, placebo-controlled trial). |
| Exposure, route, schedule | Oral urolithin A (1000 mg/day) for 4 months. |
| Comparator / duration | Placebo-controlled, randomized, double-blind; 4-month intervention. |
| Endpoint / numeric result | Improved a muscle-endurance measure and some plasma mitochondrial biomarkers; several endpoints (e.g. 6-minute walk distance, muscle ATP) did NOT reach statistical significance. |
| What it did NOT establish | Mixed functional/biomarker result; no lifespan, disease-outcome, or healthy-aging-longevity claim is supported. |
Interventions
Primary reference
https://doi.org/10.1001/jamanetworkopen.2021.44279
Exact identifier confirmed against the primary record via Crossref/ClinicalTrials.gov where stated in the citation status; anything marked needs_primary_fulltext is not yet confirmed.